Drug Profile

TST 105

Alternative Names: TST-105

Latest Information Update: 30 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Transcenta Holding
Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

05 May 2025 Preclinical trials in Solid tumours in China (Parenteral), prior to may 2025 (Transcenta holdings pipeline, May 2025)
05 May 2025 Pharmacodynamics data from a preclinical trial in Solid tumour released by Transcenta Holding Limited (Transcenta holdings pipeline, May 2025)
27 Dec 2023 Transcenta Holding Limited files a PCT patent application with WIFO for Anti-fgfr2b antibody in World

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com